603259.SH
XD药明康
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 155.84
−4.31%Year over year
Reported trailing growth
- Revenue
- +17.9%
- EBITDA
- —
- EBIT
- +86.2%
- EPS
- +80.8%
- Free cash flow
- +23.2%
- Operating cash flow
- +31.9%
Forward estimates
Based on analyst estimates
- Revenue
- +34.0%
- EBITDA
- +17.4%
- EPS
- +8.2%
Three-year CAGR
- Revenue
- +4.9%
- EBITDA
- +30.2%
- EBIT
- +31.0%
- Net income
- +29.5%
- EPS
- +30.6%
- Free cash flow
- +161.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026